Cristiane C Lamas1,2, Lara E Coelho3, Beatriz J Grinsztejn3, Valdilea G Veloso3. 1. Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Avenida Brasil 4365-Manguinhos, Rio de Janeiro, RJ, CEP 21.040-900, Brazil. cristianelamas@gmail.com. 2. Universidade do Grande Rio, Rio de Janeiro, Brazil. cristianelamas@gmail.com. 3. Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Avenida Brasil 4365-Manguinhos, Rio de Janeiro, RJ, CEP 21.040-900, Brazil.
Abstract
Community-acquired pneumonia represents the most frequent bacterial infection in patients with HIV/AIDS. PURPOSE: We aimed to assess variables associated with lower respiratory tract infection (LRTI) among HIV-infected adults using ART. METHODS: A cohort study of HIV-infected patients aged ≥18 years, enrolled from 2000 to 2015, on ART for at least 60 days, with primary outcome as the 1st episode of LRTI during follow-up. The independent variables included were sex at birth, age, race/skin color, educational level, tobacco smoking, alcohol use, cocaine use, diabetes mellitus, CD4 count, HIV viral load, influenza and pneumococcal vaccination. Extended Cox proportional hazards models accounting for time-updated variables were fitted to assess LRTI predictors. RESULTS: 2669 patients were included; median follow-up was 3.9 years per patient. LRTI was diagnosed in 384 patients; incidence rate was 30.7/1000 PY. In the unadjusted Cox extended models, non-white race [crude hazard ratio (cHR) 1.28, p = 0.020], cocaine use (cHR 2.01, p < 0.001), tobacco smoking (cHR 1.34, p value 0.007), and HIV viral load ≥400 copies/mL (cHR 3.40, p < 0.001) increased the risk of LRTI. Lower risk of LRTI was seen with higher educational level (cHR 0.61, p < 0.001), rise in CD4 counts (cHR 0.81, p < 0.001, per 100 cells/mm3 increase), influenza (cHR 0.60, p = 0.002) and pneumococcal vaccination (cHR 0.57, p < 0.001). In the adjusted model, aHR for CD4 count was 0.86, for cocaine use 1.47 and for viral load ≥400 copies 2.20. CONCLUSIONS: LRTI has a high incidence in HIV-infected adults using ART. Higher CD4 counts and undetectable viral loads were protective, as were pneumococcal and influenza vaccines.
Community-acquired pneumonia represents the most frequent bacterial infection in patients with HIV/AIDS. PURPOSE: We aimed to assess variables associated with lower respiratory tract infection (LRTI) among HIV-infected adults using ART. METHODS: A cohort study of HIV-infectedpatients aged ≥18 years, enrolled from 2000 to 2015, on ART for at least 60 days, with primary outcome as the 1st episode of LRTI during follow-up. The independent variables included were sex at birth, age, race/skin color, educational level, tobacco smoking, alcohol use, cocaine use, diabetes mellitus, CD4 count, HIV viral load, influenza and pneumococcal vaccination. Extended Cox proportional hazards models accounting for time-updated variables were fitted to assess LRTI predictors. RESULTS: 2669 patients were included; median follow-up was 3.9 years per patient. LRTI was diagnosed in 384 patients; incidence rate was 30.7/1000 PY. In the unadjusted Cox extended models, non-white race [crude hazard ratio (cHR) 1.28, p = 0.020], cocaine use (cHR 2.01, p < 0.001), tobacco smoking (cHR 1.34, p value 0.007), and HIV viral load ≥400 copies/mL (cHR 3.40, p < 0.001) increased the risk of LRTI. Lower risk of LRTI was seen with higher educational level (cHR 0.61, p < 0.001), rise in CD4 counts (cHR 0.81, p < 0.001, per 100 cells/mm3 increase), influenza (cHR 0.60, p = 0.002) and pneumococcal vaccination (cHR 0.57, p < 0.001). In the adjusted model, aHR for CD4 count was 0.86, for cocaine use 1.47 and for viral load ≥400 copies 2.20. CONCLUSIONS: LRTI has a high incidence in HIV-infected adults using ART. Higher CD4 counts and undetectable viral loads were protective, as were pneumococcal and influenza vaccines.
Authors: Sayonara R Ribeiro; Paula M Luz; Dayse P Campos; Ronaldo I Moreira; Lara Coelho; André Japiassu; Fernando Bozza; Valdilea G Veloso; Genevieve Chene; Beatriz Grinsztejn Journal: Antivir Ther Date: 2014-01-20
Authors: G C Baldwin; D P Tashkin; D M Buckley; A N Park; S M Dubinett; M D Roth Journal: Am J Respir Crit Care Med Date: 1997-11 Impact factor: 21.405
Authors: O S Søgaard; J Reekie; M Ristola; D Jevtovic; I Karpov; M Beniowski; S Servitskiy; P Domingo; P Reiss; A Mocroft; O Kirk Journal: J Infect Date: 2013-01-24 Impact factor: 6.072
Authors: Harish Jasti; Eric M Mortensen; David Scott Obrosky; Wishwa N Kapoor; Michael J Fine Journal: Clin Infect Dis Date: 2008-02-15 Impact factor: 9.079
Authors: Hanalise V Huff; Paloma M Carcamo; Monica M Diaz; Jamie L Conklin; Justina Salvatierra; Rocio Aponte; Patricia J Garcia Journal: Int J Environ Res Public Health Date: 2022-06-12 Impact factor: 4.614
Authors: S Camon; C Quiros; N Saubi; A Moreno; M A Marcos; Y Eto; S Rofael; E Monclus; J Brown; T D McHugh; J Mallolas; R Perello Journal: BMC Infect Dis Date: 2018-04-19 Impact factor: 3.090
Authors: Hannah M Garcia Garrido; Anne M R Mak; Ferdinand W N M Wit; Gino W M Wong; Mirjam J Knol; Albert Vollaard; Michael W T Tanck; Arie Van Der Ende; Martin P Grobusch; Abraham Goorhuis Journal: Clin Infect Dis Date: 2020-06-24 Impact factor: 9.079
Authors: Amy Price; Grace McHugh; Victoria Simms; Robina Semphere; Lucky G Ngwira; Tsitsi Bandason; Hilda Mujuru; Jon O Odland; Rashida A Ferrand; Andrea M Rehman Journal: EClinicalMedicine Date: 2021-11-13